1.
|
Phase: Phase III Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-301, NCT00704730
|
|
2.
|
Phase: Phase II, Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-202, NCT00596648
|
|
3.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-201, NCT00704288
|
|
4.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-203, NCT00940225
|
|
5.
|
Phase: Phase II Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-205, NCT01068782
|
|
6.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-001, NCT00215605
|
|
7.
|
Phase: Phase I Type: Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-002, NCT00960492
|
|
8.
|
Phase: Phase I Type: Treatment Status: Completed Age: 20 and over Sponsor: Pharmaceutical / Industry Protocol IDs: CA205-001, NCT01018745
|
|
9.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Pharmaceutical / Industry Protocol IDs: XL184-008, NCT01100619
|
|
10.
|
Phase: Phase I Type: Biomarker/Laboratory analysis, Treatment Status: Closed Age: 18 and over Sponsor: Other Protocol IDs: 11-005, NCT01347788
|